Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DB-1305 + DB-1311 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DB-1305 | DB1305|DB 1305|BNT325|BNT 325|BNT-325 | TROP2 Antibody 18 | DB-1305 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting TROP2 conjugated to a DNA topoisomerase I inhibitor, which potentially results in antitumor activity (Ann Oncol 34 (2023): S480). | |
| DB-1311 | DB 1311|DB1311|BNT324|BNT-324|BNT 324 | CD276 Antibody 21 | DB-1311 is an antibody-drug conjugate (ADC) comprising a B7-H3 (CD276) antibody conjugated to the topoisomerase inhibitor P1021, which potentially decreases growth of B7-H3 (CD276)-expressing tumors (Cancer Res (2023) 83 (7_Supplement): 2967). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06953089 | Phase II | DB-1305 + DB-1311 BNT327 + DB-1311 | DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |